ライフサイエンスコーパス: approved drug

1 th at least one Food and Drug Administration-approved drug.

2 y targeted by a Food and Drug Administration-approved drug.

3 on-label or off-label treatment with an FDA-approved drug.

4 rmacological intervention using a clinically approved drug.

5 large-scale cell cycle profiling of 884 FDA-approved drugs.

6 molecule compounds including most of the FDA-approved drugs.

7 hanisms of action distinct from those of the approved drugs.

8 ion protease inhibitors beyond the currently approved drugs.

9 that encode proteins that are the targets of approved drugs.

10 ble by US Food and Drug Administration (FDA)-approved drugs.

11 me, are also the largest class of targets of approved drugs.

12 r the metabolism of approximately 90% of FDA-approved drugs.

13 al processes, are the major target class for approved drugs.

14 consuming Food and Drug Administration (FDA)-approved drugs.

15 ntially applicable to diseases with very few approved drugs.

16 ds including US Food and Drug Administration-approved drugs.

17 in vitro alone and in combination with other approved drugs.

18 enhanced the antileukemia effect of already-approved drugs.

19 essing the problem of a decreasing stream of approved drugs.

20 es, and these were compared to a database of approved drugs.

21 virtual screening to reprofile existing FDA-approved drugs.

22 er HIV-1 reactivation, into the group of FDA-approved drugs.

23 ustom collection of known bioactives and FDA approved drugs.

24 r previous studies screened a library of FDA-approved drugs.

25 adrenoceptor blockers with emphasis on newly approved drugs.

26 may affect the optimal response to currently approved drugs.

27 in both properties and of these, 67 are FDA-approved drugs.

28 in the range of Food and Drug Administration-approved drugs.

29 areas for drug discovery, and mechanisms of approved drugs.

30 mechanisms of action to those of previously approved drugs.

31 syltransferases (UGTs) metabolize 15% of FDA approved drugs.

32 the DrugBank (a database of experimental and approved drugs): 28% of the predicted hits were reported

33 nsive molecular fit computations on 3671 FDA approved drugs across 2335 human protein crystal structu

34 cinnamon and a Food and Drug Administration-approved drug against urea cycle disorders, upregulates

35 se 2 (JAK2)-STAT3-calprotectin axis with FDA-approved drugs, alone and in combination with HER2 inhib

36 romoglycate), a Food and Drug Administration-approved drug already in use for the treatment of asthma

37 to meet this important goal, since currently approved drugs already have well-established safety and

38 his can be accomplished using the clinically approved drug AMD3100, a small molecule inhibitor of SDF

39 In addition, a Food and Drug Administration-approved drug ameliorates the outcome of TBI in mouse, b

40 Here the FDA-approved drug amlexanox was tested for its ability to re

41 oactive natural products, one of which is an approved drug and many of which are potent drug leads.

42 FdUrd), a U.S. Food and Drug Administration-approved drug and metabolite of 5-fluorouracil, causes D

43 Repositioning approved drug and small molecules in novel therapeutic a

44 One thousand seven hundred and sixty-six FDA-approved drugs and 259 experimental drugs were screened

45 tely 34%) Food and Drug Administration (FDA)-approved drugs and account for a global sales volume of

46 uciferase reporter assay to screen 3,756 FDA-approved drugs and bioactive compounds for induction of

47 in gene expression in response to 1,309 FDA-approved drugs and bioactives (CMap).

48 developed a chemical screen to identify FDA-approved drugs and biologically active compounds that mo

49 the literature in the past five years, from approved drugs and clinical candidates to examples under

50 gh screening US Food and Drug Administration-approved drugs and clinical trial compounds; however, no

51 rmed 2 complementary screens to identify FDA-approved drugs and drug-like small molecules with activi

52 the coverage of all the targets of currently approved drugs and future candidate targets, alongside e

53 argets of Food and Drug Administration (FDA)-approved drugs and it too proves to be highly effective.

54 a moderate throughput chemical screen of FDA-approved drugs and natural compounds, and found that red

55 screen of 1987 compounds, including many FDA-approved drugs and natural products.

56 e learning classifier to prioritize ADRs for approved drugs and pre-clinical small-molecule compounds

57 mate group is a key structural motif in many approved drugs and prodrugs.

58 g components of this metabolic switch, using approved drugs and starvation approaches followed by cel

59 ces, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chem

60 and U.S. Food and Drug Administration (FDA) approved drugs and was found to have an affinity of 100

61 ess of development stage (early discovery to approved drug) and source (natural product or synthetic)

62 eclinical stage to 8.2% among mechanisms for approved drugs, and varies dramatically among disease ar

63 KV prophylaxis and treatment, repurposing of approved drugs appears to be a viable and immediate solu

64 As no Food and Drug Administration-approved drugs are currently available for treatment of

65 New drugs are needed for HAT because the approved drugs are few, toxic, and difficult to administ

66 s in therapy and as biological probes, 7% of approved drugs are purported to have no known primary ta

67 mitoxantrone out of more than 600 clinically approved drugs as a direct selective inhibitor of human

68 ioning of Food and Drug Administration (FDA)-approved drugs as cancer treatments, which were employed

69 c EGFR signaling and identify a class of FDA-approved drugs as capable of restoring chemosensitivity

70 wed focus on the repositioning of clinically approved drugs as potential anti-malarial therapies.

71 now allows for in silico predictions of FDA-approved drugs as treatments against infection diseases.

72 atment of PTCL due to the advent of recently approved drugs as well as new targeted agents currently

73 We identified two approved drugs, ascorbic acid 6-palmitate and salmon spe

74 s from the literature suggested that two FDA-approved drugs (atorvastatin and dasatinib), approved fo

75 esults provide a rationale to reposition the approved drug auranofin for clinical evaluation in the t

76 Currently, the only approved drug available for mass treatment is ivermectin

77 re are no Food and Drug Administration (FDA) approved drugs available for preventing or treating AHF,

78 ounds and 20 US Food and Drug Administration-approved drugs based on their predicted ability to bind

79 We discovered that an approved drug, Bithionol, inhibits host caspases and als

80 Of medical significance, the clinically approved drug Bortezomib partially restored protein leve

81 Adenosine is a Food and Drug Administration-approved drug, but very little is known about the effect

82 Prediction of new disease indications for approved drugs by computational methods has been based l

83 dings of 114 US Food and Drug Administration-approved drugs by extracting all clinically DILI-related

84 n vitro These data demonstrate that specific approved drugs can be characterized in vitro for their a

85 emical compound, we predicted that seven FDA-approved drugs can be repurposed as novel anti-cancer th

86 easing interstitial potassium by diet or FDA-approved drugs can reverse the muscle weakness, fatigue-

87 Importantly, the FDA-approved drug celecoxib re-establishes the AKT/miR-199a-

88 tivity than the Food and Drug Administration-approved drugs cisplatin and oxaliplatin.

89 approximately 6,000 compounds that included approved drugs, clinical trial drug candidates and pharm

90 As with all drugs, especially newly approved drugs, clinicians must consult the package inse

91 Utilizing a phenotypic screen of an approved drug collection, we found that delta-tocopherol

92 ts were randomly assigned to receive ART (an approved drug combination derived from US Department of

93 cient to explain the superiority of many FDA-approved drug combinations in the absence of drug synerg

94 Currently approved drug combinations result largely from empirical

95 safety deficiencies was similar among never-approved drugs compared with those with delayed approval

96 Intravenous immunoglobulin (IVIG) is a FDA-approved drug containing IgG.

97 Therefore, approved drugs could rapidly be made available for a new

98 e identify ETV6-NTRK3 as a target of the FDA-approved drug crizotinib (Xalkori).

99 to ALK kinase inhibitors, including the FDA-approved drug crizotinib.

100 tioning approach to suppress these using FDA approved drugs currently available for non-transplant in

101 le inhibitors of cyclophilins, including the approved drug cyclosporine, greatly reduced the viabilit

102 uding the Food and Drug Administration (FDA)-approved drugs dasatinib, bosutinib, and saracatinib tha

103 ntify intracellular kinase engagement by the approved drug, dasatinib.

104 s study, using in silico screening of an FDA-approved drug database, we identified proton pump inhibi

105 re show that a combination of two clinically approved drugs, decitabine and gemcitabine, reduced HIV

106 , effectively distinguishing these from 1065 approved drug decoys with an area under curve value of 9

107 This combination of approved drugs demonstrates a novel ability to reverse T

108 Inhibition of RANK using the approved drug denosumab may be a therapeutic drug candid

109 ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality,

110 three lead compounds include the clinically approved drug, digoxin; the marine-derived natural produ

111 s selection criteria, we identified four FDA-approved drugs directed against four different PN target

112 available on MEDLINE is a rich source of FDA-approved drug-disease indication as well as drug-repurpo

113 n a primary CD4(+) T cell model that the FDA-approved drug disulfiram reactivates latent HIV-1 withou

114 ~40 mug/mL, which is similar to that for the approved drug efavirenz and ~1000-fold greater than for

115 compare etirinotecan pegol versus one of the approved drugs (eg, pegylated liposomal doxorubicin or t

116 d proportion of Food and Drug Administration-approved drug-eluting or bare-metal stents.

117 hese results highlight the potential for FDA-approved drug enhancement of adeno-associated virus gene

118 th anti-AR potency comparable to a newly FDA-approved drug Enzalutamide.

119 mTOR complex 1 (mTORC1) with the clinically approved drug everolimus (RAD001) or inhibition of mTORC

120 ort of future clinical studies for the newly approved drug Farxiga or any combination therapy contain

121 ition of Rock activity, using the clinically approved drug fasudil, prevented dendritic network disor

122 three US Food and Drug Administration (FDA)-approved drugs--ferumoxytol, heparin and protamine--in s

123 The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis

124 ptosis than Memantine, the most recently FDA-approved drug for AD treatment.

125 SPO) via a combination of disulfiram, an FDA approved drug for alcoholism, and (64)CuCl2 (termed (64)

126 There is an approved drug for biallelic knock-down of the APOB gene

127 Ranolazine is an approved drug for chronic stable angina that acts by sup

128 aftor), a Food and Drug Administration (FDA)-approved drug for clinical application to patients with

129 and cis-diols (such as mannitol, a safe FDA approved drug for diuresis) through particle size measur

130 umor growth in mice than sorafenib, the only approved drug for HCC.

131 There is currently no FDA-approved drug for humans infected with orthopoxviruses.

132 nidone, a Food and Drug Administration (FDA)-approved drug for idiopathic pulmonary fibrosis, for its

133 We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is

134 ACF, a US Food and Drug Administration (FDA)-approved drug for nononcological use in humans, as a nov

135 principle is shown on chlorin as a partially approved drug for photodynamic cancer therapy, the conce

136 al function and identify TIG as a clinically approved drug for RB1-deficient TNBC.

137 , was the first Food and Drug Administration-approved drug for the postdocetaxel setting.

138 vior was not affected by acamprosate, an FDA-approved drug for the treatment of alcoholism, suggestin

139 The only US Food and Drug Administration-approved drug for the treatment of ALS, Riluzole, has at

140 manage HD symptoms, in addition to the only approved drug for the treatment of chorea in HD, tetrabe

141 Apolipoprotein B (ApoB)-ASO is an FDA approved drug for treating familial hypercholesterolemia

142 Sorafenib remains the only approved drug for treating patients with advanced hepato

143 N-butyldeoxynojyrimicin (miglustat), an approved drug for treating type 1 Gaucher disease, was f

144 FTY720 (fingolimod), an FDA-approved drug for treatment of multiple sclerosis, has b

145 Riluzole, the approved drug for use in ALS, modulates neuronal stress

146 chemical collection that included previously approved drugs for compounds that induced cold sensitive

147 prioritized the Food and Drug Administration-approved drugs for Crohn's disease.

148 ing FDA (U.S. Food and Drug Administration) -approved drugs for development of anti-TB agents may dec

149 g United States Food and Drug Administration-approved drugs for hypertension, human immunodeficiency

150 om the infected cell, are currently the only approved drugs for influenza, but have recently been sho

151 We previously screened a library of FDA-approved drugs for inhibitors of coronavirus replication

152 g knowledge that is crucial for applying FDA-approved drugs for new diseases.

153 We assembled and screened 1012 FDA-approved drugs for off-label broad-spectrum efficacy aga

154 d, reliable and systematic identification of approved drugs for originally unintended uses.

155 The mechanisms of action of the approved drugs for RRMS provide a strong foundation for

156 However, given few or no approved drugs for the diseases of highest medical urgen

157 ics represent a powerful class of clinically approved drugs for the prevention and treatment of vario

158 dentification of new drug candidates and FDA-approved drugs for the treatment of monogenic and comple

159 omalidomide are Food and Drug Administration-approved drugs for the treatment of various ailments.

160 We interrogated a library of FDA-approved drugs for their ability to block infection of h

161 d United States Food and Drug Administration-approved drugs for their autophagy-stimulating potential

162 y is an important step in the repurposing of approved drugs for treatment of emerging coronaviruses.

163 rgatroban and lepirudin are well studied and approved drugs for treatment of HIT.

164 There are nine approved drugs for treatment of RRMS.

165 ed that Guanabenz acetate (Wytensin), an FDA-approved drug formerly used as an antihypertensive agent

166 argets of food and drug administration (FDA)-approved drugs from drug perturbations followed by mRNA

167 termates to the Food and Drug Administration-approved drug FTY720 (fingolimod, Gilenya) or vehicle co

168 targets of U.S. Food and Drug Administration-approved drugs, functional cross-talk between these drug

169 diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH

170 the integrated stress response using the FDA-approved drug guanabenz increases oligodendrocyte surviv

171 restin2-GFP reporter, we identified four FDA-approved drugs, halcinonide, fluticasone, clobetasol, an

172 These findings suggest that 4PBA, an FDA-approved drug, has potential as a therapeutic interventi

173 Many US FDA-approved drugs have been developed through productive in

174 , novel pathways of resistance to clinically approved drugs have been identified and validated.

175 Several currently available FDA-approved drugs have been shown to enhance autophagy, and

176 of neurological disorders however to date no approved drugs have progressed to market.

177 y of the examples in this article consist of approved drugs; however, in some cases, ongoing developm

178 Here, we report that the FDA approved drug hydralazine is a bona fide activator of th

179 Clinically approved drugs identified as potential readthrough agent

180 S Food and Drug Administration-approved (FDA-approved) drugs identified the MPT antagonist tigecyclin

181 s and, moreover, show that rapamycin, an FDA approved drug, improves learning and memory and reduces

182 evaluation of this novel combination of FDA-approved drugs in clinical trials.

183 This review highlights approved drugs in different therapeutic classes, includi

184 sted the efficacy of approximately 1,000 FDA-approved drugs in improving the aggregation phenotype of

185 ts an economic methodology to reposition FDA approved drugs in organ transplantation.

186 We screened 1549 FDA-approved drugs in the DrugBank database on an ensemble o

187 multiple pathophysiological features, and as approved drugs in wide human use could be considered for

188 including 1250 Food and Drug Administration-approved drugs, in a novel cell-based assay, followed by

189 Several FDA-approved drugs, including selective estrogen receptor mo

190 As the number of approved drugs increases, clinicians will need to choose

191 ar target for DMF and show that a clinically approved drug inhibits M1 and K63 chain formation in TLR

192 tor of Pho84, a Food and Drug Administration-approved drug, inhibits TORC1 signaling and potentiates

193 ve automatically assigned over a thousand of approved drugs into these MoA categories.

194 ardial therapies and that disulfiram, an FDA-approved drug, is a promising candidate for drug repurpo

195 ranofin, a U.S. Food and Drug Administration-approved drug, is a rational strategy to treat lung canc

196 e report that a Food and Drug Administration-approved drug known to inhibit ribotoxic stress response

197 Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral mo

198 d drug clearance data were obtained from FDA-approved drug labels and publicly available databases co

199 by examining the adverse event terms in FDA approved drug labels.

200 d in U.S. Food and Drug Administration (FDA) approved drug labels.

201 In this study, we screened the FDA-approved drug library for agents that share significant

202 iloprost, both Food and Drug Administration-approved drugs, may be useful in treating allergic disea

203 new dual-action compound related to the FDA-approved drug memantine, representing an uncompetitive/f

204 rmore, we showed that treatment with the FDA-approved drug metformin also rescued memory.

205 we show how GSCs can be targeted by the FDA-approved drug mibefradil, which inhibits the T-type calc

206 ed in 13 patients utilising on/off label FDA approved drugs (n = 9), clinical trials (n = 3) and sing

207 lly modulated in vitro using an existing FDA-approved drug, Nitazoxanide, suggesting a possible avenu

208 e the standard, Food and Drug Administration-approved drug of last resort, vancomycin, and the yet-to

209 ing adverse effects in therapy with the sole approved drug of this class, linezolid.

210 ns are of particularly relevance because FDA-approved drugs of the thiazolidinedione class currently

211 and is a common reason for withdrawal of an approved drug or discontinuation of a potentially new dr

212 Thus, the addition of this currently approved drug or more specific efflux pump inhibitors to

213 ons of existing Food and Drug Administration-approved drugs or bioactive compounds that are already u

214 een to identify Food and Drug Administration-approved drugs or other bioactive compounds that could e

215 target of U. S. Food and Drug Administration-approved drugs, our strategy could be effectively applie

216 at dasatinib, a Food and Drug Administration-approved drug, potently binds Hck with high selectivity.

217 Book (Truven Health Analytics); Orange Book: Approved Drug Products with Therapeutic Equivalence Eval

218 e, the US Food and Drug Administration (FDA)-approved drug pyrvinium delays and/or inhibits disease i

219 virus intasome have shown that all three FDA-approved drugs, raltegravir (RAL), elvitegravir and dolu

220 The FDA approved drug rapamycin increases lifespan in rodents an

221 ptimization campaigns and clinical stage and approved drugs, reflecting their increasingly important

222 CNQ-type K(+) channel openers, including FDA-approved drug retigabine (ezogabine), show antidepressan

223 Analysis of our database of U.S. FDA approved drugs reveals that 59% of unique small-molecule

224 In addition, treatment with the FDA-approved drug risperidone ameliorates the targeted repet

225 halomyelitis virus were treated with the FDA-approved drug ritonavir using a dosing regimen that resu

226 gabatrin, a known inactivator of GABA-AT and approved drug (Sabril) for the treatment of infantile sp

227 from the Food and Drug Administration (FDA)-approved drug-set libraries.

228 Screening FDA-approved drugs streamlines the pipeline for this process

229 the hits in the Food and Drug Administration-approved drug subset revealed compounds that seem to act

230 lation elongation using existing, clinically approved drugs, such as the rapalogs, would provide clea

231 found that the Food and Drug Administration-approved drugs, sunitinib and dasatinib, prohibit brain

232 At least 30% of all approved drugs target GPCRs; thus, Gpr126 represents an

233 Furthermore, many FDA-approved drugs target such proteins.

234 However, clinically approved drugs targeting D2 DAR display poor selectivity

235 allels to Food and Drug Administration (FDA)-approved drugs targeting the related human immunodeficie

236 significantly more frequent among the never-approved drugs than among those with delayed approvals (

237 ine (SAS), a US Food and Drug Administration-approved drug that blocks system x(c)(-).

238 Since meclizine is an approved drug that crosses the blood-brain barrier, it m

239 with miglustat, a European Medicines Agency-approved drug that has been shown to reduce NPC1-associa

240 N-acetylcysteine (NAC) is an FDA-approved drug that has long been used to treat chronic o

241 ates identified, disulfiram (DSF), is an FDA-approved drug that has previously yielded disappointing

242 There is no vaccine and only a single approved drug that provides no benefit for those in grav

243 cs target the lipid II pathway, there are no approved drugs that act on its C55-P precursor.

244 RAS-directed therapeutics, there are no FDA-approved drugs that are broadly effective against RAS-dr

245 Host-directed immunotherapy with clinically approved drugs that augment prostaglandin E2 levels in t

246 created a murine adaptation to identify FDA-approved drugs that can rescue affected pathways.

247 to identify the Food and Drug Administration-approved drugs that could be used to treat this tumor.

248 severe H7N9 influenza and identifies six FDA-approved drugs that could potentially be repurposed as H

249 to H7N9 infection, and we identified six FDA-approved drugs that could potentially be repurposed to t

250 different condition, to identify clinically approved drugs that have anti-HIV activity.

251 viral replication and the development of 24 approved drugs that have five different targets on vario

252 ilarity clustering identified unexpected FDA-approved drugs that induced DNA damage, including clinic

253 actinomycin, we initially identified two FDA-approved drugs that primed latent HIV-1 infection in T c

254 inhibitor, in a small molecule screen of FDA-approved drugs that rescued neuronal dysfunction and red

255 identified four Food and Drug Administration-approved drugs that selectively affect viability of TSC-

256 Our goal was to identify other FDA-approved drugs that synergize with statins to further en

257 entia, and is potentially treatable with FDA-approved drugs that target B cells.

258 In the presence of a non-toxic FDA-approved drug, the nanorings were quickly disassembled a

259 slate promising biological findings to novel approved drug therapies and discuss the attendant challe

260 including alterations for which there is an approved drug, there are therapies in clinical or precli

261 Considering that oxytocin is an FDA-approved drug, this work reveals a potential novel and s

262 ax releases this antagonism and is the first approved drug to target a protein-protein interaction.

263 There is currently no approved drug to treat patients with AR.

264 discuss screening of libraries of previously approved drugs to identify nonobvious antimicrobial adju

265 Currently, there are no approved drugs to specifically lower Lp(a).

266 D-cycloserine as immediately accessible, FDA-approved drugs to treat AUDs.

267 hway that can be targeted by new and already approved drugs to treat fragile X patients.

268 rposed US Food and Drug Administration (FDA)-approved drugs to treat hydrocephalus.

269 IMPORTANCE There are currently no approved drugs to treat infections with alphaviruses.

270 Drug repurposing is the application of approved drugs to treat new indications.

271 When treated with the FDA-approved drugs tramadol and escitalopram oxalate, they r

272 wth factor kinases MEK1/2, including the FDA-approved drug trametinib.

273 Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which

274 membrane by treatment with the nontoxic FDA approved drug, trimethoprim.

275 linear combinations of ring systems from FDA approved drugs, up to three rings in length and up to fo

276 s bezafibrate is a well-tolerated clinically approved drug used for managing lipidemia, our findings

277 fin, a US Food and Drug Administration (FDA)-approved drug used therapeutically for rheumatoid arthri

278 We propose that 4-MU, already an approved drug used to treat biliary spasm, could be repu

279 that these pathways are targeted by several approved drugs used to treat the symptoms of RA highligh

280 ther drugs, we conducted a screen of 446 FDA approved drugs using two Dck-defective BXH-2 derived mur

281 d that during the past 40 years, 153 new FDA-approved drugs, vaccines, or new indications for existin

282 Following a screen of 1,200 approved drugs, we identified Chicago Sky Blue 6B as the

283 Using a screen composed of other FDA approved drugs, we identified dipyridamole, used for the

284 creening the NIH clinical collections of FDA-approved drugs, we identified tacrolimus (FK-506) as the

285 ds including US Food and Drug Administration-approved drugs were identified that favorably modulate a

286 To do this, a comprehensive panel of FDA-approved drugs were tested in human cells and in animal

287 ed a high-throughput chemical screen for FDA approved drugs, which affect HDR in cancer cells.

288 ticancer drugs by jointly using a clinically approved drug with known side effects and drug-drug inte

289 re several clinical trials in which recently approved drugs with known activity in AITL are paired wi

290 lue in identifying promising combinations of approved drugs with potent anticancer activity for furth

291 be used as an approach for prioritizing FDA-approved drugs with repurposing potential, which could a

292 ue molecular signatures for prioritizing FDA-approved drugs with repurposing potential.

293 olecular compounds were interrogated for FDA approved drugs with specific inhibition of this axis.

294 ication to the clinic is to identify already approved drugs with the potential for activating or inhi

295 without any US Food and Drug Administration-approved drugs with this specific target.

296 leaving only 13 Food and Drug Administration-approved drugs with unknown targets; the number of drugs

297 Repurposing already-approved drugs with well-characterized toxicology and ph

298 atocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor.

299 n, a criterion necessary because a potential approved drug would be administered chronically.

300 matory leukotrienes were in the range of the approved drug zileuton, which further underlines the bio